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A B S T R A C T
Patients with primary refractory or relapsed acute myeloid leukemia (RR-AML) have very poor prognosis. Due
to limited treatment options, some patients are treated with hypomethylating agents (HMAs) due to their
tolerability. Little is known about the role of allogeneic hematopoietic stem cell transplantation (HSCT) fol-
lowing HMA therapy in this setting. We retrospectively analyzed an international cohort of 655 RR-AML patients
who received HMA therapy to study patterns and outcomes with HSCT. Only 37 patients (5.6%) patients un-
derwent HSCT after HMA therapy. The conditioning regimen was myeloablative in 57% and nonmyeloablative
in 43%. Patients received matched unrelated donor, matched sibling, haploidentical and mismatched unre-
lated HSCT in 56%, 24%, 16% and 4% of cases, respectively. Acute GvHD and chronic GvHD were observed in
40% and 17% of patients. While the median OS for the entire cohort of patients was 15.3 months (95% CI 9.5
Financial disclosure: See Acknowledgments on page 1757.
Note: The results of this research were presented at American Society of Hematology, Atlanta, GA, December 2017.
* Correspondence and reprint requests: Amer M. Zeidan, MBB, MHS, Section of Hematology, Department of Internal Medicine, Yale School of Medicine, 333
Cedar St, New Haven, CT 06510-3222.
E-mail address: amer.zeidan@yale.edu (A.M. Zeidan).
https://doi.org/10.1016/j.bbmt.2018.03.025
1083-8791/© 2018 American Society for Blood and Marrow Transplantation.
Biol Blood Marrow Transplant 24 (2018) 1754–1770
Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.org
– 21.7 months), OS reached 29.7 months (95% CI 7.01 – not-reached) for patients who achieved a complete
remission (CR) to HMA and no intervening therapies between HMA therapy and HSCT. Our study suggests
that HMA therapy can effectively bridge some patients with RR-AML to HSCT.
© 2018 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Patients with primary refractory and relapsed (RR) acute
myeloid leukemia (AML), particularly older adults, have dismal
outcomes and limited therapeutic options are available [1].
Allogeneic hematopoietic stem cell transplantation (HSCT) is
the only potentially curative treatment in this setting [2,3].
However, achieving disease control is generally necessary for
successful HSCT outcomes. Intensive chemotherapy is the
commonly used modality to achieve CR for patients with RR
AML; however, complete remission (CR) rates generally do
not exceed 20% to 40% and intensive therapy is associated with
increased risks of mortality and morbidity as well as pro-
longed hospitalization. Given their tolerability,
hypomethylating agents (HMAs) have been used in pa-
tients with AML, usually in frontline setting, who are unfit
for intensive chemotherapy [1]. In a prior multicenter study,
we have shown that HMAs result in CR/CR with incomplete
count recovery (CRi) in 16% of patients with RR AML while
offering the opportunity of outpatient therapy and lower risk
of therapy-related complications [4]. Most of the data re-
garding transplant outcomes among patients with RR AML
comes from trials and analyses of patients who received in-
tensive salvage chemotherapy [5]. Several intensive
chemotherapy regimens have been studied; however, there
is no clear evidence of superiority of any particular regimen
[5]. In contrast, little is known about the transplant out-
comes for those patients with RR AML who are treated with
HMA as salvage therapy before transplantation.
METHODS
Using a large multicenter international database, we analyzed charac-
teristics and clinical outcomes of the subgroup of RR AML patients who
underwent HSCT after HMA salvage therapy. Data of patients treated with
HMAs for RR AML were collected for a period spanning 2006 to 2016, from
7 centers in the United States and 4 centers in Europe. For the subgroup of
patients who underwent HSCT after HMA therapy, we assessed type of graft
and conditioning regimen, lines of therapy post-HMA and before HSCT, a
well as any post-HSCT therapies. Furthermore, we analyzed the rate and se-
verity of acute and chronic graft-versus-host disease (GVHD) as well as 30-
day and long-term mortality post-transplantation and their respective
predictors. Kaplan-Meier methods were used to estimate overall survival (OS)
from the start of HMA therapy to death or end of follow-up.
RESULTS
Of 655 patients in the database, 16% achieved a CR/CRi
with HMA therapy, and only 37 patients (5.6% of the entire
cohort) underwent HSCT at one point after receiving HMA
salvage therapy (Table 1). Of these patients, 16 (43.2%) had
relapsed and 21 (56.8%) had primary refractory AML. At the
time of HMA therapy, only 1 patient had favorable risk karyo-
type, whereas 69% and 23% had intermediate-risk and poor-
risk karyotypes, respectively. Azacitidine and decitabine were
used in 34% and 66% of patients, respectively. Patients had
received a median of 1 line of therapy (range, 1 to 7) before
HMA therapy. Of all patients who underwent HSCT, 23 (62%)
had achieved a response (CR, CRi, or hematologic improve-
ment [HI]) to HMA therapy whereas the other 14 (38%) did
not. Twenty-four (65%) patients went directly to HSCT after
completing HMA therapy while 13 (35%) patients received
additional therapy between HMA therapy and HSCT (Table 2).
Of patients receiving no additional therapies between HMA
and HSCT, a total of 16 patients had responded to HMA
therapy (CR = 7, CRi = 8, HI = 1). Of patients who received some
type of post-HMA therapy before HSCT, 7 patients had
achieved a prior response to HMA (CR = 4, CRi = 2, HI = 1).
The median duration between last day of HMA therapy
and HSCT was 50 days (range, 6 to 210 days). Approximate-
ly 57% of patients received myeloablative conditioning therapy
while the other 43% received nonmyeloablative condition-
ing regimens. Most patients received a matched unrelated
donor transplant (56%) or a matched sibling transplant (24%),
whereas 16% and 4% of patients received a haploidentical or
a mismatched unrelated HSCT, respectively (Table 2).
Acute GVHD was observed in 40% of patients, with 75%
developing grade of 1 or 2 GVHD and 25% developing grade
3 or 4 GVHD. Acute GVHD affected skin (30%), mouth (10%),
gastrointestinal tract (45%), and liver (15%). Furthermore, 17%
of patients developed chronic GVHD, which was limited in
Table 1
Patient Characteristics of the 37 Transplanted Patients
Patient characteristics
Male/female sex 17/20 (46/54)
Age, yr 56 (22–71)
Disease status
Relapsed 16 (43.2)










No response to HMA 14 (38)
Therapy between stop of HMA therapy and HSCT
Yes/no 13/24 (35/65)
Type of therapy administered (18 therapies










Type of therapy administered (13 therapies
prescribed to 7 patients):






Data are presented as n/n (%), mean (range), or n (%).
CPX-351 indicates liposomal formulation containing a fixed combination of
cytarabine and daunorubicin in a 5:1 molar ratio; CLAG, cladribine, cytarabine,
and filgrastim; MEC: mitoxantrone, etoposide and cytarabine; FLAG,
fludarabine, cytarabine, granulocyte colony-stimulating factor; SGI-110,
guadecitabine; ASP-2215, gilteritinib.
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75% and extensive in 25% of patients (Table 2). Chronic GVHD
most commonly affected skin (40%), but also affected eyes and
mouth (20%), gastrointestinal tract (20%), and liver (20%). After
HSCT, 7 (19%) patients received further lines of therapy, with
epigenetic therapy (HMA or histone deacetylase inhibitor
therapy) (58%) being most commonly used whereas chemo-
therapy was rarely used (8%).
The median OS for the entire cohort of 37 patients who
underwent HSCT after HMA therapy was 15.3 months (95%
confidence interval [CI], 9.5 to 21.7 months) from the start
of HMA therapy. This was statistically significantly longer than
the median OS for all other 618 patients, who did not receive
a HSCT after HMA therapy (OS, 6.4 months; 95% CI, 5.7 to 6.9
months; P < .0001). The median OS was 14.6 months (95% CI,
9.5 months to not reached) for patients with no therapies ad-
ministered between HMA and HSCT and 15.3 months (95%
CI, 9.4 months to not reached) for patients with at least 1
therapy in between HMA and HSCT, respectively (P = .3) (Figure
1A).
For patients, who underwent subsequent HSCT without
intervening therapies between HMA and HSCT, median OS
was 16.8 months (95% CI, 9.5 months to not reached) for the
16 patients who achieved a response to HMA therapy (CR/
CRi/HI), whereas it was 14.5 months (95% CI, 6.7 months to
not reached; P = .4) for the 8 patients with either stable disease
or progressive disease (Figure 1B).
For patients without intervening therapies between HMA
and HSCT, median OS was 29.7 months (95% CI, 7 months to
not reached) for patients who achieved a CR to HMA and 14.6
months (95% CI, 9.47 months to not reached) for those not
achieving CR (P = .6).
DISCUSSION
In summary, in one of the largest reported cohorts of pa-
tients with RR AML treated with HMAs, we determined that
a minority of patients underwent HSCT after completion of
HMA therapy.
While the median OS of the patients who underwent HSCT
after HMA therapy was significantly longer compared with
patients who did not undergo HSCT, only about 25% of the
24 patients who went to HSCT directly after HMA therapy
were long term survivors (reached a plateau on the Kaplan-
Meier survival curve), which translates into just 6 patients
of the original 655-person cohort (<1%). Importantly, the OS
for patients who achieved a CR with HMAs and went direct-
ly to HSCT was not statistically significantly different from
patients who achieved a CR with HMAs but did not undergo
HSCT (29.7 months versus 25.3 months; P = .8). Further-
more, it did not seem to make a difference whether patients
achieved a response to HMA therapy or not and whether pa-
tients went directly to HSCT after HMA therapy or had any
other therapy after receiving HMA and before HSCT (Figure
1). These findings could argue against a benefit specific to
HMA therapy when used as a bridge therapy to HSCT. While
patients who achieved a CR with HMAs and thereafter un-
derwent HSCT without intervening therapy had a median OS
reaching 30 months, this subgroup was too small to make any
conclusions whether they had a statistically significantly pro-
longed OS compared with patients who did not achieve a CR
with HMA therapy.
Our study indicates that while HMAs can allow outpa-
tient administration with lower toxicity compared with
salvage intensive chemotherapy and can be used as a bridge
Table 2
Transplant Characteristics for Patients who underwent HSCT after HMA for RR AML
All Patients (N = 37) Patients with no Subsequent
Therapies between HMA and
HSCT (n = 24)
Patients with Subsequent
Therapies between HMA and
HSCT (n = 13)
Type of graft (n = 25)
Matched sibling 6 (24) 4 (25) 2 (22.2)
Matched unrelated donor 14 (56) 9 (56.2) 5 (55.6)
Mismatched unrelated 1 (4) 0 (0) 1 (11.1)
Haplotransplant 4 (16) 3 (18.8) 1 (11.1)
Type of conditioning regimen (n = 14)
Ablative 8 (57.1) 7 (63.6) 1 (33.3)
Nonablative 6 (42.9) 4 (36.4) 2 (66.7)
Acute GVHD:
Presence of acute GVHD (n = 25) 10 (40) 6 (40) 4 (40)
Grade of acute GVHD (n = 8)
1 3 (37.5) 2 (50) 1 (25)
2 3 (37.5) 1 (25) 2 (50)
3 1 (12.5) 0 (0) 1 (25)
4 1 (12.5) 1 (25) 0 (0)
Organ affected in acute GVHD (n = 20)
Skin 6 (30) 4 (33.3) 2 (25)
Eyes 2 (10) 2 (16.7) 0 (0)
Gut 9 (45) 5 (41.7) 4 (50)
Liver 3 (15) 1 (8.3) 2 (25)
Chronic GVHD
Presence of chronic GVHD (n = 24) 4 (16.7) 3 (21.4) 1 (10)
Severity of chronic GVHD (n = 4)
Limited 3 (75) 3 (100) 0 (0)
Extensive 1 (25) 0 (0) 1 (100)
Organ affected in chronic GVHD (n = 5)
Skin 2 (40) 2 (66.7) 0 (0)
Mouth 1 (20) 1 (33.3) 0 (0)
Gut 1 (20) 0 (0) 1 (50)
Liver 1 (20) 0 (0) 1 (50)
Data are presented as n (%).
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to HSCT, only a minority of patients with RR AML were able
to undergo transplantation and the long survival rate was quite
limited. As most patients do very poorly regardless of HMA
response and regardless of receiving HSCT, improved treat-
ments are urgently needed for patients with RR AML.
Combining HMAs with investigational therapies could lead
to better outcomes in this difficult to treat patient population.
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